A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin) in Patients With Solid Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ME 344 (Primary) ; Topotecan
- Indications Cervical cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors MEI Pharma
- 10 Mar 2017 Results published in the Investigational New Drugs
- 05 Jul 2016 Status changed from completed to discontinued due to lack of efficacy.
- 21 Apr 2016 Status changed from active, no longer recruiting to completed.